tiprankstipranks
ProQR Secures $8.1 Million for Rett Syndrome RNA Therapy
Company Announcements

ProQR Secures $8.1 Million for Rett Syndrome RNA Therapy

Story Highlights

Pick the best stocks and maximize your portfolio:

The latest announcement is out from ProQR ( (PRQR) ).

ProQR Therapeutics has announced an $8.1 million funding boost from the Rett Syndrome Research Trust, raising the total investment to $9.1 million to advance their RNA editing collaboration. This funding will accelerate the development of AX-2402, a therapeutic candidate targeting the R270X mutation in the MECP2 gene associated with Rett Syndrome, into clinical trials, potentially paving the way for treatments that address a significant unmet medical need in this area.

More about ProQR

ProQR Therapeutics is a biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA editing technology. This platform is designed to create a new class of medicines for both rare and prevalent diseases, addressing unmet medical needs through precise RNA editing.

YTD Price Performance: 67.17%

Average Trading Volume: 1,446,002

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $341.6M

See more insights into PRQR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyProQR Therapeutics announces $8.1M in new funding from RSRT
TipRanks Auto-Generated NewsdeskProQR Strengthens RNA Editing Team with Key Appointment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App